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Hospitals (ATIH). Costs and outcomes were discounted at 4% through 30 years and 
2% thereafter. Robustness of results was assessed using sensitivity analyses. The 
assessed outcomes were the incremental cost per quality-adjusted life-year (QALY) 
gained and total life-years gained (LYG). Results: This study will inform public 
decision making about reimbursement of mild-to-moderate OSAHS treatments. 
CPAP was associated with higher costs and QALYs compared with dental devices, 
lifestyle advice and no treatment. Several sensitivity analyses were undertaken 
and it was found that the most sensitive parameters were related to sleepiness and 
cardiovascular inputs. Further investigation (clinical trial/observational study) of 
treatment effects on these parameters is needed. ConClusions: This analysis is 
the first to assess the cost-effectiveness of treatments in mild-to-moderate OSAHS 
patients in France. The technical report of this research will be available on the 
HAS website at the time of the congress (November 2014).
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objeCtives: Allergic rhinitis – hay fever and mite hypersensitivity - is a prevalent 
and increasingly common condition, causing considerable morbidity and eco-
nomic burden to society. A minority of patients have an indication for subcutane-
ous immunotherapy (SCIT). SCIT using extracts of tree pollen, grass pollen and/or 
house dust mite is common practice in The Netherlands, Europe and beyond. SCIT 
is widely reimbursed, but very few prospective cost-effectiveness studies have been 
done. Methods: An open-label, 2-year, multicenter, randomized controlled trial 
with two parallel treatment arms was performed, comparing SCIT + usual care (UC) 
with UC alone, using online resource use and labor productivity questionnaires, and 
electronic versions of EQ-5D®, SF-36® and a global subjective assessment of symp-
toms (GA). Primary endpoints were the costs per QALY, costs per successfully treated 
patient and the cost per additional symptom-free day. A Generalized Estimation 
Equation (GEE) model was estimated with mean two-week health care/societal costs 
as dependent variable, followed by a 1000-iteration bootstrap procedure. Results: 
A total of 183 adult patients aged 18 to 45 years with persistent moderate to severe 
allergic rhinitis due to one (43%) or more (57%) allergies (93 SCIT+UC, 90 UC) were 
included. There were no significant differences at baseline. The percentage of 
patients that reported to be treated successfully was 36% in SCIT and 20% in UC 
after two years. Other health outcomes did not differ between SCIT and Usual Care. 
Two-year costs of SCIT were 2946 Euro per patient. There was no difference in other 
costs. Cost per additional successfully treated patient were about 15,000 Euro. For 
the other outcomes, SCIT was dominated by UC. ConClusions: This study could 
not support the cost-effectiveness of SCIT. A restriction in the indication of SCIT 
to patients with severe persistent rhinitis, not sufficiently responsive to maximum 
symptomatic therapy may improve cost-effectiveness.
PRS56
imPaCt of allERgEn immunothERaPy on Quality of lifE and hEalth 
CaRE CoStS in adultS and ChildREn With gRaSS PollEn-induCEd 
allERgiC RhinitiS in gERmany
Najib M.1, Westerhout K.Y.2, Verheggen B.2, Schreder C.H.3
1Stallergenes, Antony, France, 2Pharmerit International, Rotterdam, The Netherlands, 3Stallergenes 
GmbH, Kamp-Lintfort, Germany
objeCtives: To determine the relative impact of treatment with Oralair®, Grazax®, 
Alutard® or symptomatic drug treatment (SDT) on clinical effects and health care 
costs in subgroups of adults and children with grass pollen-induced allergic rhinitis 
(AR) in Germany. The cost-effectiveness of Oralair® has been demonstrated in a 
mixed population in previous research. Methods: The effects of three years of drug 
treatment on quality-adjusted life years (QALYs) and associated costs were assessed 
using a Markov model with a nine-year time horizon. Symptom score data were 
extracted, and the relative efficacy on QALYs was assessed through a network meta-
analysis (i. e. indirect comparison) of placebo-controlled, clinical trial data in adults 
and children. Patient symptom scores were translated into the impact on quality of 
life by means of published sources. Costs associated with drug treatment and other 
health care resources, including Statutory Health Insurance payments and patient 
co-payments, were estimated. The incremental costs and QALYs were generated 
accordingly. The uncertainty around the model outcomes was determined by means 
of sensitivity analyses. Results: In adults, the analysis predicted more QALYs for 
Oralair® relative to Grazax®, 0.008 (95%CI: -0.043; 0.062) and Alutard®, 0.028 (95%CI: 
-0.029; 0.093), combined with incremental costs of -€ 1,272 (95%CI: -€ 1,530; -€ 999) 
and -€ 129 (95%CI: -€ 389; € 160) per patient, respectively. Hence, Oralair is dominant 
relative to Grazax® and Alutard® in adults. The incremental cost-effectiveness ratio 
was estimated at € 15,503 per QALY relative to SDT. Similar results were observed 
in children, with the exception of Alutard® (lack of data). The sensitivity analyses 
suggest that results were mostly driven by drug-specific clinical effects on symptom 
score, drug costs, inputs for immunotherapy discontinuation, and length of the pol-
len season. ConClusions: Oralair® is cost-effective relative to Grazax®, Alutard® 
and SDT in grass pollen-induced AR in Germany. Findings were confirmed again 
and supported by extensive sensitivity analyses.
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alone from 3.6% to 45.8%, and omalizumab from 0% to 6%. Annual hospitalizations 
rates and emergency visits decreased by 78% and 75% respectively. The ICER was 
1800€ per controlled patient per year. ConClusions: Managing asthma patients 
in a specialized AC is cost-effective and has significant impact on patient control, 
indicating better survival and quality of life for the patient according to published 
literature evidence.
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objeCtives: A health economic assessment was conducted to determine the 
relative impact of treatment with Oralair® or Grazax® on clinical effects and 
health care costs in patients with grass pollen-induced allergic rhinitis (AR) in 
Germany. Methods: The effects of three years of drug treatment on symptom-
free days (SFDs) and associated costs were assessed using a health economic 
Markov model with a nine-year time horizon. The relative efficacy on SFDs was 
assessed through a network meta-analysis (i. e. indirect comparison) of 4-year, 
placebo-controlled, clinical trial data. Costs associated with drug treatment and 
other health care resources, including Statutory Health Insurance payments and 
patient co-payments, were calculated. The incremental costs and SFDs gained for 
Oralair® relative to Grazax® were generated accordingly. The uncertainty around 
the model outcomes was determined by means of sensitivity analyses. Results: 
The base case analysis over 9 years predicts a total of 206.6 discounted SFDs for 
Oralair®relative to 205.1 for Grazax®, thus resulting in 1.5 (95%CI: -25.0; 29.3) addi-
tional SFDs gained with Oralair®. Total discounted costs are estimated at € 1,696 and 
€ 2,968 for Oralair® and Grazax®, respectively, with incremental costs predicted at 
-€ 1,272 (95%CI: -€ 1,530; -€ 999). Hence, Oralair® may be classified as the dominant 
strategy, as additional effects are combined with considerable cost savings. The 
sensitivity analyses suggest that results were mostly driven by drug-specific clini-
cal effects on SFD, inputs for immunotherapy discontinuation, and length of the 
pollen season. The predicted cost savings were driven by the difference in treat-
ment costs. ConClusions: Oralair® is cost-effective relative to Grazax®in patients 
with grass pollen-induced AR in Germany. Findings are confirmed by extensive 
sensitivity analyses.
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objeCtives: To evaluate the potential economic impact of the 100% whey-based 
partially hydrolyzed infant formula (PHF-W) in comparison with a cow’s milk stand-
ard formula (SF) in the prevention of atopic dermatitis (AD) in at-risk children at 
the age periods 0–12 and 0–36 months in Russia. Methods: The Excel model was 
constructed to estimate costs of artificial feeding with PHF-W vs SF and expected 
AD cases treatment. The model was based on the results of meta-analysis of rand-
omized controlled trials (RCTs), literature data and the results of the expert survey. 
The costs of artificial feeding and AD treatment were calculated from the positions 
of different payers: health care system, family, and society as a whole. The incre-
mental cost-effectiveness ratio (ICER) per averted AD case was calculated for PHF-W 
vs SF. Results: From health care system point of view the use of PHF-W uniquely 
lead to cost savings. If we consider all costs from the societal perspective PHF-W 
vs SF requires additional costs in the first year of baby’s life, but in leads to cost 
savings in a 3-year horizon. From the perspective of the at-risk child’s family arti-
ficial feeding costs will increase from 266 to 408 Euro for PHF-W vs SF. However the 
likelihood of AD development in a child will decrease from 15 to 8% in the first year 
and from 27 to 19% over three years and accordingly this will prevent AD treatment 
costs. ConClusions: Using PHF-W for the AD preventionin high-risk children have 
benefits for both the health system and for individual family.
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objeCtives: In France, continuous positive airway pressure (CPAP) is recom-
mended as first-line treatment for patients with severe OSAHS or mild-to-mod-
erate OSAHS with high cardiovascular risk. Dental devices are recommended 
as second-line treatment for these patients and can be suggested as first-line 
treatment for mild-to-moderate OSAHS patients without high cardiovascular 
risk. Lifestyle advice is recommended for overweight patients. This study aims to 
assess the cost-effectiveness of these treatments for mild-to-moderate OSAHS 
patients. Methods: This study was commissioned by the French National 
Authority for Health (HAS) and followed their recommendations. A Markov model 
was developed to simulate the lifetime progression of a cohort of mild-to-mod-
erate adult OSAHS patients. CPAP was compared with dental devices, lifestyle 
advice and no treatment. Daytime sleepiness, cardiovascular disease and road 
traffic accidents were taken into account. Clinical parameters were taken from 
international publications. Costs were retrieved from the French national health 
insurance databases: Assurance Maladie and Technical Agency of Information on 
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Pollinex Quattro® and SDT in grass pollen-induced AR in Spain. Findings are con-
firmed by extensive sensitivity analyses.
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objeCtives: Endobronchial valve therapy (EBV) is an innovative treatment that 
has been shown to be safe and effective in selected subgroups of patients with 
severe emphysema. The objective of our study was to assess the cost-effectiveness 
of valve treatment in the German health care system when compared to medical 
management. Methods: Clinical data from a subset of the Endobronchial Valve 
for Emphysema Palliation Trial (VENT) provided information about clinical events, 
health-related quality of life, and disease staging through 12 months. This informa-
tion was subsequently used as input to a previously published Markov model to 
project longer-term disease progression, mortality, and health resource utilization. 
From this combined analysis, we computed the 5-year and 10-year incremental 
cost-effectiveness ratio (ICER) in euros per quality-adjusted life year (QALY). Costs 
and effects were discounted at 3% per year. Results: EBV therapy led to clini-
cally meaningful disease restaging at 12 months (37.8% of cohort improved staging, 
compared to 0% in control). Over 5 years, EBV was projected to increase survival 
from 66.4% to 70.7%, and to add 0.22 QALYs. Costs were estimated to increase by € 
10,299, resulting in an ICER of € 46,322/QALY. Over 10 years, 0.41 QALYs were gained 
at additional cost of € 10,425, yielding an ICER of € 25,142/QALY. ConClusions: Our 
model-based analysis suggests that EBV leads to clinically meaningful changes in 
disease staging and progression when compared to medical management, with 
resulting gains in unadjusted and quality-adjusted life expectancy. Relative to the 
acknowledged willingness-to-pay threshold of € 50,000/QALY, our results indicate 
EBV is a cost-effective therapy in the German health care system.
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objeCtives: Allergic rhinitis (AR) affects 10-20% of the US population, with treat-
ment costs exceeding $6 billion annually and has been shown to have a substantial 
impact on productivity. In the U. S. AR is estimated to result in 3.5 million lost work 
days and 2 million lost school days annually. AZ/FP is an intranasal formulation 
of azelastine hydrochloride and fluticasone propionate in an advanced delivery 
system indicated for the relief of symptoms of seasonal AR (SAR). Patients treated 
with AZ/FP experience significantly greater and faster symptom relief in compari-
son to first-line therapy in trials, and thus have the potential to positively impact 
workplace productivity. We use an economic model to calculate the economic effects 
on workplace productivity associated with moving AZ/FP from third-tier to second-
tier pricing and reimbursement. Methods: Population is SAR sufferers seeking 
treatment. AZ/FP is assumed to gain market share annually with second-tier pric-
ing. Time horizon is one year and five years. Four step approach: (1) estimate total 
number of AR-related symptomatic days; (2) calculate total number of AR-related 
episodes per year multiplied by number of days per episode; (3) estimate number of 
these days that occur during a standard 5-day work week; & (4) Estimate proportion 
of AR symptomatic days resulting in absenteeism or presenteeism. Results: For 
a typical health plan, the estimate of expected number of absenteeism and pres-
enteeism days per AZ/FP patient associated with moving AZ/FP from Tier 3 to Tier 
2 resulted in a reduction of 4,729 AR-symptomatic days annually. Total workplace 
cost savings ranged from $168,838 (Year 1) to $190,937 (Year 5), with the proportional 
effects on absenteeism and presenteeism being roughly equal. ConClusions: AZ/
FP offers an appropriate means of adhering to AR practice guidelines and improv-
ing outcomes. This workplace productivity model shows that the added benefits to 
employers could be substantial.
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objeCtives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta 
agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was devel-
oped to assess the potential societal cost benefits of improved inhalation technique 
with DuoResp® Spiromax® compared with Symbicort® Turbuhaler®– a DPI delivering 
the same FDC – in the management of adult patients with persistent asthma and 
chronic obstructive pulmonary disease (COPD) in Sweden. Methods: The eligible 
adult patient population was based on statistics from the National Board of Health 
and Welfare in Sweden. Societal costs (lost productivity) were based on the annual 
number of work-days lost for asthma and COPD patients in Sweden and the United 
Kingdom (UK), respectively, and the average daily cost of sick leave in Sweden. 
Frequency of poor inhalation technique with Symbicort® Turbuhaler® and the sub-
sequent increased risk of unscheduled health care events were taken from a large 
(n= 1,664) cross-sectional, Italian observational study. The estimated reduction in the 
proportion of patients with poor inhalation technique with DuoResp® Spiromax® 
objeCtives: Severe asthma is a major cause of morbidity and mortality around 
the world, associated with a heavy societal burden. The aim of this study was to 
evaluate the economic value of omalizumab in the treatment of adult patients 
with severe allergic asthma in Greece, from a societal perspective, based on data 
collected from a clinical trial (INNOVATE) and real-world evidence (RWE) from a 
prospective observational study conducted in Greece. Methods: A Markov cohort 
model was developed in Microsoft Excel to compare the costs and outcomes of 
omalizumab plus standard therapy (ST, primarily comprised ICS, LABA and SABA) 
versus ST alone. The time horizon was that of a lifetime. Both direct and indirect 
costs were incorporated. Health outcomes considered were Quality Adjusted Life 
Years (QALYs). Costs and QALYs were discounted annually at 3.5%. Unit costs 
were taken from publically available sources. Productivity losses were calculated 
based on published data, while utility values were taken from the INNOVATE 
study. Deterministic and probabilistic sensitivity analyses were undertaken to 
test the robustness of the model results. Results: The addition of omalizumab 
to ST led to an incremental cost per QALY gained of € 27,888 based on INNOVATE 
trial and € 27,255 based on the RWE. The model appeared to be most sensitive to 
changes in the time horizon and the age of retirement. Results of the probabilistic 
sensitivity analysis showed that the probability of omalizumab being cost effec-
tive was 58% and 84%, at a willingness to pay threshold of € 30,000 and € 40,000, 
respectively. ConClusions: Omalizumab appears to be a cost-effective treatment 
option for adult patients with severe allergic asthma compared with ST in Greece, 
confirmed by both trial and real-world data.
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objeCtives: To assess the cost-effectiveness (CE) of indacaterol/glycopyrronium 
(QVA149; 85µg/43µg) as a maintenance bronchodilator treatment of adult patients 
with Chronic Obstructive Pulmonary Disease (COPD) versus salmeterol/flutica-
sone (SFC; 50µg/500µg). Methods: A CE model of micro-simulation over a 3-, 5-, 
10-year and lifetime horizon was developed from the perspective of the Spanish 
National Healthcare System. Patients progress through subsequent COPD stages 
based on their baseline characteristics and considering the natural decline of 
Forced Expiratory Volume in 1 second (FEV1) and exacerbation rate. In the model 
this is counteracted by treatment-associated FEV1 improvement from baseline and 
exacerbation rate reduction associated to each treatment vs. placebo, which were 
obtained by direct and indirect comparison of primary data from TORCH (SFC vs. 
placebo), SHINE (QVA149 vs. placebo) and ILLUMINATE (QVA149 vs SFC) clinical 
trials. The considered outcomes were life years (LY) gained and quality-adjusted 
life years (QALYs). Cost estimates (Euros 2014) include drugs, disease management 
and mild/severe exacerbation expenditures from Spanish health care cost data-
bases and publications with a discount rate of 3% for costs and effects. Results: 
QVA149 has shown to be less costly and more effective than the fixed combination 
of SFC with respect to both LY and QALYs gained. The cost per patient treated with 
QVA149 over a 3-, 5-, 10-year and lifetime period was estimated to be € 108, € 182, 
€ 305, and € 467 lower than with SFC, which resulted from avoiding exacerbation 
costs and decreasing maintenance cost in relation to slowing COPD progression. 
Therefore, QVA149 was estimated to be dominant over SFC with respect to both 
cost-effectiveness and cost-utility. ConClusions: Due to its higher effectiveness 
in improving FEV1 and reducing COPD exacerbations, QVA149 has shown to be 
more cost-effective than SFC.
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objeCtives: To determine the relative impact of treatment with Oralair®, Grazax®, 
Pangramin®, Pollinex Quattro®, and symptomatic drug treatment (SDT) on clinical 
effects and health care costs in patients with grass pollen-induced allergic rhinitis 
(AR) in Spain. Methods: The effects of three years of drug treatment on quality-
adjusted life years (QALYs) and costs were assessed using a Markov model with 
a nine-year time horizon. Symptom score data were extracted, and the relative 
efficacy on QALYs was assessed through a network meta-analysis (i. e. indirect 
comparison) of 3-year, placebo-controlled, clinical trial data. Patient symptom scores 
were translated into the impact on quality of life by means of published sources. 
Costs associated with drug treatment and other health care resources were calcu-
lated. The incremental costs and QALYs gained were generated accordingly. The 
uncertainty around the model outcomes was determined by means of sensitiv-
ity analyses. Results: The base case analysis over 9 years estimated incremental 
QALYs of 0.005 (95%CI: -0.024; 0.038), 0.016 (95%CI: -0.034; 0.063), 0.059 (95%CI: 0.024; 
0.107), and 0.143 (95%CI: 0.102; 0.195) when Oralair® was compared to Grazax®, 
Pangramin®, Pollinex Quattro® and SDT, respectively. Corresponding incremental 
costs were -€ 1,063 (95%CI: -€ 1,306; -€ 779), € 109 (95%CI: €206; € 428), € 572 (95%CI: € 321; 
€ 864), and € 1,360 (95%CI: € 1,110; € 1,649). Hence, Oralair® was predicted as domi-
nant relative to Grazax®, while ICERs of € 6,931/QALY, € 9,703/QALY, and € 9,517/QALY 
were estimated relative to Pangramin®, Pollinex Quattro®, and SDT, respectively. 
Apart from drug costs, the sensitivity analyses suggest that results were mostly 
driven by drug-specific symptom score values, duration of the pollen season, and 
inputs for immunotherapy discontinuation. At a willingness-to-pay threshold of 
€ 20,000, the probability of Oralair® being the most cost-effective treatment option 
is 65%. ConClusions: Oralair® is cost-effective relative to Grazax®, Pangramin®, 
